Localised ALK-positive histiocytosis in lung with EML4::ALK fusion

被引：3
|
作者：
Zou, Long [1 ]
Lu, Tao [1 ]
Li, Mei [1 ]
Wang, Anqi [2 ]
Zhang, Zixin [2 ]
Pan, Boju [1 ]
Sun, Jian [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Pathol, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Med Res Ctr, Beijing, Peoples R China
来源：
PATHOLOGY | 2024年 / 56卷 / 04期
关键词：
D O I：
10.1016/j.pathol.2023.09.014
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：604 / 606
页数：3
相关论文
共 50 条
  • [41] An ALK Immunohistochemical Pitfall: ALK-Positive Histiocytosis Versus Angiomatoid Fibrous Histiocytoma
    Chang, Justin
    Greenwood, Anna C.
    Kidd, Chelsea
    Diaz-Perez, Julio A.
    Smith, Steven Christopher
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2025,
  • [42] ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion
    Chang, Kenneth Tou En
    Tay, Amos Zhi En
    Kuick, Chik Hong
    Chen, Huiyi
    Algar, Elizabeth
    Taubenheim, Nadine
    Campbell, Janine
    Mechinaud, Francoise
    Campbell, Martin
    Super, Leanne
    Chantranuwat, Chavit
    Yuen, S. T.
    Chan, John K. C.
    Chow, Chung W.
    MODERN PATHOLOGY, 2019, 32 (05) : 598 - 608
  • [43] Combination ALK and MEK Inhibition in ALK-Positive Lung Cancer
    Ashton, J.
    Shrestha, N.
    Bland, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S857 - S857
  • [44] A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK
    Anai, Satoshi
    Takeshita, Masafumi
    Ando, Nobuhisa
    Ikematsu, Yuuki
    Mishima, Shohei
    Ishida, Koichi
    Inoue, Kouji
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : E126 - +
  • [45] A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK
    Liu, Lirong
    Hou, Fangfang
    Liu, Yufeng
    Li, Wenzhu
    Zhang, Haibo
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (01): : 2 - 6
  • [46] Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC)
    Bauer, Todd M.
    Martini, Jean-Francois
    Besse, Benjamin
    Lin, Chia-Chi
    Soo, Ross A.
    Riely, Gregory J.
    Ou, Sai-Hong Ignatius
    Toffalorio, Francesca
    Abbattista, Antonello
    Thurm, Holger
    Camidge, D. Ross
    Kao, Steven
    Chiari, Rita
    Gadgeel, Shirish
    Felip, Enriqueta
    Shaw, Alice T.
    Solomon, Benjamin J.
    CANCER RESEARCH, 2020, 80 (16)
  • [47] Phase separation of EML4–ALK in firing downstream signaling and promoting lung tumorigenesis
    Zhen Qin
    Honghua Sun
    Meiting Yue
    Xinwen Pan
    Liang Chen
    Xinhua Feng
    Xiumin Yan
    Xueliang Zhu
    Hongbin Ji
    Cell Discovery, 7
  • [48] MONOTHERAPY TREATMENT WITH CYTARABINE FOR ALK-POSITIVE HISTIOCYTOSIS IN AN INFANT
    Chao, Karen
    Becktell, Kerri
    Suchi, Mariko
    Phelan, Rachel
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [49] ALK-positive histiocytosis presenting as a solitary pulmonary nodule
    Yuan, Chang-Tsu
    Chen, Jin-Shing
    Huang, Yen-Lin
    Zhang, Man-San
    Hsieh, Min-Shu
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (01) : 7 - 7
  • [50] EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
    Koivunen, Jussi P.
    Mermel, Craig
    Zejnullahu, Kreshnik
    Murphy, Carly
    Lifshits, Eugene
    Holmes, Alison J.
    Choi, Hwan Geun
    Kim, Jhingook
    Chiang, Derek
    Thomas, Roman
    Lee, Jinseon
    Richards, William G.
    Sugarbaker, David J.
    Ducko, Christopher
    Lindeman, Neal
    Marcoux, J. Paul
    Engelman, Jeffrey A.
    Gray, Nathanael S.
    Lee, Charles
    Meyerson, Matthew
    Janne, Pasi A.
    CLINICAL CANCER RESEARCH, 2008, 14 (13) : 4275 - 4283
12345